Laina Crowthers
Obstetrics & Gynecology · Providence, RINPI 1215953716
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $4,038 with a category attached, or 61.9%. AbbVie accounts for 66.8% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $2,263 and has fallen 93.8% since, to $141 in 2025.
Across 80 payments — averaging $50.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Sumitomo Pharma America, Inc.$148
- Pfizer$137
- Sage Therapeutics, LLC$117
- Exeltis, USA Inc.$115
- Merck$114
- plus $707 from 19 others
What the payments were for
- Speaking & faculty fees$2,50062%
- Food & beverage$1,52038%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 13 | $2,699 |
| Sumitomo Pharma America, Inc. | 7 | $148 |
| Pfizer | 8 | $137 |
| Sage Therapeutics, LLC | 5 | $117 |
| Exeltis, USA Inc. | 5 | $115 |
| Merck | 7 | $114 |
| Myovant Sciences Inc. | 5 | $95 |
| Hologic Sales And Service, LLC | 2 | $80 |
| Mylan Pharmaceuticals Inc. | 4 | $69 |
| Astellas Pharma US Inc | 3 | $57 |
| Coopersurgical, Inc. | 3 | $55 |
| Mayne Pharma Commercial LLC | 2 | $49 |
| Bayer | 2 | $40 |
| Exact Sciences | 2 | $36 |
| Roche Diagnostics Corporation | 2 | $33 |
| Smith+Nephew | 1 | $26 |
| Covidien LP | 1 | $26 |
| Therapeuticsmd, Inc. | 1 | $24 |
| Shield Therapeutics Inc | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Lupin Inc. | 1 | $17 |
| Organon | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Avion Pharmaceuticals | 1 | $14 |
How this compares
$4,038 in reported general payments places this provider in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 23 | $10,766 |
| Estradiol | 82 | $4,388 |
| YuvafemEstradiol | 24 | $4,188 |
| Estradiol (Once Weekly)Estradiol | 21 | $1,448 |
| Raloxifene Hcl | 17 | $1,294 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 43 | $941 |
| Clobetasol Propionate | 30 | $878 |
| ValacyclovirValacyclovir Hcl | 20 | $838 |
| Triamcinolone Acetonide | 35 | $165 |
| Ketoconazole | 17 | $163 |
| Fluconazole | 24 | $147 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $137 | $10,76623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 139 obstetrics & gynecology providers in Rhode Island.
Other obstetrics & gynecology in Providence
- Warren HuberProvidence$50K
- Lisa BoyleProvidence$30K
- Renee EgerProvidence$24K
- Gary WhartonProvidence$22K
- Christine FoleyProvidence$21K
- Cara MathewsProvidence$21K
- Michael BeitleProvidence$9K
- Ogechukwu EzikeProvidence$7K
- Beata DizoglioProvidence$6K
- Michele GangeProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.